Previous 10 | Next 10 |
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer - Study to Evaluate Intravenous Nemvaleukin in Combination With Pembrolizumab Compared to Investigator's Choice Chemotherapy - PR Newswire DUBLIN , ...
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer - Second Fast Track Designation for Nemvaleukin - PR Newswire DUBLIN , Oct. 25, 2021 /PRNewswire/ -- A...
Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021 PR Newswire DUBLIN , Oct. 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesd...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Higher yields as well as uncertainty over inflation, supp...
Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder PR Newswire DUBLIN , Oct. 18, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that LYBALVI ® (olanzapine and samido...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Most investors are more familiar with large-cap companies, which have a market cap of $10 billion or more, than with mid- or small-cap companies. Mid-cap stocks have a market cap between $2 billion and $10 billion, while sm...
On Monday, Biogen Inc. ( NASDAQ:BIIB ) shares edged higher 1% after Teva Pharmaceutical Industries Ltd ( TLV:TEVA ) settled the Vumerity lawsuit. The lawsuit claimed that Teva’s proposed generic version of Vumerity would violate three Alkermes Plc ( NASDAQ:ALKS ) ...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
--News Direct-- This summer, Alkermes continued its annual "Alkermes in Action" volunteer program, which offers employees opportunities to support local communities with hands-on activities that align with the company's values and embody compassion. Employees recently came together to b...
Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference PR Newswire DUBLIN , Sept. 22, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healt...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...